Dermira Inc. (NASDAQ:DERM)’s share price rose 2.4% on Thursday . The stock traded as high as $31.90 and last traded at $31.77, with a volume of 88,124 shares trading hands. The stock had previously closed at $31.04.

DERM has been the topic of several research analyst reports. Zacks Investment Research raised shares of Dermira from a “sell” rating to a “hold” rating in a research report on Tuesday, June 14th. Needham & Company LLC reissued a “buy” rating and issued a $46.00 price objective on shares of Dermira in a research report on Wednesday, June 22nd. Leerink Swann reissued a “buy” rating and issued a $46.00 price objective (up from $39.00) on shares of Dermira in a research report on Tuesday, May 10th. Finally, Wedbush increased their price objective on shares of Dermira from $42.00 to $46.00 and gave the company an “outperform” rating in a research report on Thursday, June 2nd. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $41.00.

The company has a 50-day moving average price of $31.82 and a 200-day moving average price of $27.43. The firm’s market cap is $1.14 billion.

Dermira (NASDAQ:DERM) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.89) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by $0.03. On average, equities research analysts anticipate that Dermira Inc. will post ($3.39) EPS for the current year.

In related news, VP Christopher M. Griffith sold 1,303 shares of Dermira stock in a transaction on Monday, August 15th. The shares were sold at an average price of $31.75, for a total value of $41,370.25. Following the transaction, the vice president now owns 44,941 shares in the company, valued at approximately $1,426,876.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Thomas G. Wiggans sold 11,000 shares of Dermira stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $29.62, for a total transaction of $325,820.00. The disclosure for this sale can be found here.

Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.